Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Robbins LLPCELH Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against Celsius Holdings, Inc.Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Celsius Holdings, Inc. (NASDAQ: CELH) securities between February 21, 2025 and June 3, 2026, inclusive (the "Class Period"). Celsius develops, processes, manufactures, markets, sells, and distributes products including energy drinks.The complaint alleges that defendants misled...
- FTC Solar Announces Waiver and Amendment to Credit AgreementFTC Solar, Inc. (Nasdaq: FTCI), a leading provider of solar tracker systems, software, and engineering services, announced today that it has entered into an amended credit agreement with its lenders, relating primarily to the principal prepayment terms and the financial covenants that would have applied during the remainder of 2026.
- ArevonArevon Achieves Top Honors in 2026 GRESB AssessmentCompany earns a 98.2 overall score, five-star rating, perfect Performance Score, and No. 1 ranking in the Americas for Solar Power Generation — Arevon Energy, Inc., a leading American energy developer, owner, and operator, announced its...
- SofWave Medical, Ltd.Sofwave to Participate in the Jefferies Private MedTech Virtual SummitSofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the Jefferies Private MedTech Virtual Summit on October 7 – 8, 2026.
- Micot's XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal DiseaseHong Kong, Oct 5, 2026 - At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), one of the world’s most influential scientific meetings in diabetes and metabolic disease, Micot Pharmaceuticals (02335.HK) presented research on XTL6001, its internally developed long-acting protein candidate and triple receptor agonist targeting GLP-1R, GCGR and MasR. The studies, covering high-quality weight management and chronic kidney disease (CKD)/diabetic kidney disease (DKD), were selected for oral presentation, bringing the Chinese-origin innovative programme onto a leading international scientific platform. From a development perspective, XTL6001 is not designed simply to maximise headline weight loss. By combining the GLP-1R, GCGR and MasR pathways, the programme aims to address weight management, glucose and lipid metabolism, body-composition optimisation and potential renal protection within a single development framework. As the GLP-1 field continues to evolve rapidly, this integrated metabolic–renal approach gives XTL6001 a differentiated profile versus conventional incretin-based therapies and provides a clearer positioning for subsequent global clinical development and potential business development opportunities. From Posters to Oral Presentations: Building International Scientific Visibility EASD and the American Diabetes Association (ADA) Scientific Sessions are among the most prominent international scientific platforms in diabetes and metabolic disease. Research on XTL6001 was first presented in two posters at ADA 2026 in June, followed by two oral presentations at EASD. The progression from posters to oral presentation provided a higher-profile forum for the same development thesis to be presented and discussed with the international scientific community. Conference selection, of course, does not substitute for clinical validation. For an early-stage innovative programme, however, repeated exposure at major international meetings can help increase visibility among clinicians, research institutions and potential industry partners. Notably, XTL6001 presented both weight-management and CKD/DKD research at the same EASD meeting. Obesity care is increasingly moving beyond “weight loss alone” toward broader management of body composition and cardiometabolic, hepatic and renal comorbidities. The ability to deliver benefits beyond weight reduction is therefore becoming an important dimension of next-generation competition. By adding MasR to the GLP-1R/GCGR combination, XTL6001 is designed to incorporate a renal-protection component into its differentiated product profile. Weight Loss, Muscle Preservation and Renal Protection: Differentiation Through a Triple-Target Mechanism According to company disclosures and publicly available scientific data, XTL6001 is a long-acting protein drug candidate and a triple receptor agonist targeting GLP-1R, GCGR and MasR. The programme has completed its Phase I study in China and has received clinical trial authorisation in both China and the United States. In the disclosed Phase I single ascending dose (SAD) study, 25 healthy participants received XTL6001 across a dose range of 37.5–300 mg, with additional participants receiving placebo. The study showed a favourable overall safety and tolerability profile. Dr. Xiangling Wang, Micot Pharma’s Chief Medical Officer (CMO), presented a systematic study comparing XTL6001 The available data also indicate that XTL6001 is designed to deliver benefits beyond the headline weight loss shown on the scale. In preclinical diet-induced obesity (DIO) mouse studies, XTL6001 demonstrated greater weight reduction than semaglutide at equivalent doses and a slower rate of weight regain after treatment discontinuation. At the same dose, and despite overall food intake being comparable to or even higher than that observed with semaglutide, weight reduction was approximately 33% greater, suggesting that the effect may be driven more by increased energy expenditure and fat utilisation than by appetite suppression alone. The studies also showed selective fat loss, restoration of the proportion of muscle mass toward normal levels, a 1.61-fold greater reduction in abdominal fat versus semaglutide, and concurrent improvements in lipid and hepatic parameters, including a reduction in LDL-C of more than 80% (87.2%) and a 90.8% reduction in hepatic triglycerides, with near-complete reversal of hepatic steatosis and normalisation of ALT. These findings point to potential utility in MASH. Importantly, the comparisons with semaglutide were generated primarily in animal studies and should not be interpreted as evidence of superior efficacy in humans. In the renal programme, publicly disclosed studies used multiple animal models of kidney disease. The rationale for the triple-target mechanism can be summarised as follows: GLP-1R primarily supports improvements in metabolism and haemodynamics; GCGR may help protect renal tubules from lipotoxic injury; and MasR is intended to address glomerular structural protection and antifibrotic activity. Together, the three pathways are designed to intervene across metabolic drivers, haemodynamic abnormalities, structural injury and fibrosis in the CKD/DKD disease cascade, rather than acting as a simple combination of independent effects. XTL6001 dose-dependently reduced 24-hour urinary albumin excretion and the urine albumin-to-creatinine ratio (UACR), while improving the glomerular filtration rate (GFR). Across different models, XTL6001 showed dose-dependent reductions in albuminuria: in STZ-induced, uninephrectomised rats, 0.5 mg/kg reduced UACR by 62.9% versus vehicle control and reduced 24-hour urinary albumin by approximately 54.7%; in the alloxan model, the reduction in UACR was approximately three times that seen with finerenone monotherapy; and in a mouse CKD model, 12 mg/kg reduced urinary albumin by 80.2%, with reductions in albuminuria reaching approximately 88% across the three models. The studies also observed reductions in serum creatinine, blood urea nitrogen and serum uric acid. These findings provide further support for the programme’s “weight management–metabolic regulation–albuminuria reduction” rationale. However, the renal benefits remain predominantly preclinical and will need to be validated in randomised controlled studies in patients with CKD/DKD. The Obesity Market Is Moving Into a Multi-Target Era — MasR Gives XTL6001 a Distinct Route The next generation of obesity therapies is already progressing from single-target GLP-1 agents toward GLP-1/GIP dual agonists, GLP-1/GCGR dual agonists and GLP-1/GIP/GCGR triple agonists. Eli Lilly’s retatrutide has advanced into Phase III development, while United Laboratories’ UBT251 is in Phase II, underscoring that “multi-target” activity alone is no longer sufficient to create a durable moat. XTL6001 is differentiated by the fact that its third target is MasR rather than GIPR. According to company disclosures, activation of the MasR pathway is associated with anti-inflammatory and antifibrotic effects, promotion of muscle-protein synthesis, improvement in mitochondrial function and induction of mitochondria-mediated thermogenesis. This gives XTL6001 a development rationale that is more naturally centred on renal protection, proteinuria and broader multi-organ metabolic benefits, rather than on cross-trial comparisons of headline weight-loss efficacy where no head-to-head evidence exists. From a capital-markets and business-development perspective, XTL6001’s successive appearances at ADA and EASD, together with its upcoming presentation of hyperuricaemic nephropathy research at ASN Kidney Week 2026, are helping the programme build continuous visibility across the diabetes, obesity and nephrology communities. Presenting at international scientific meetings is not a transaction in itself, nor can it replace human efficacy data, but it can create additional touchpoints with potential licensing, co-development and regional partners. Ultimately, the asset’s value will depend on whether clinical studies in humans can validate the hypotheses around quality of weight loss, body-composition improvement and renal protection; whether its safety and tolerability profile remains competitive; and whether indications such as CKD/DKD can demonstrate reproducible and clinically translatable benefits. If these elements are progressively validated, XTL6001 could establish a more distinctive global development path in the increasingly crowded GLP-1 landscape through a combined positioning around high-quality weight management, metabolic improvement and potential renal protection.
- Micot's XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal DiseaseHong Kong, Oct 5, 2026 - At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), one of the world’s most influential scientific meetings in diabetes and metabolic disease, Micot Pharmaceuticals (02335.HK) presented research on XTL6001, its internally developed long-acting protein candidate and triple receptor agonist targeting GLP-1R, GCGR and MasR. The studies, covering high-quality weight management and chronic kidney disease (CKD)/diabetic kidney disease (DKD), were selected for oral presentation, bringing the Chinese-origin innovative programme onto a leading international scientific platform. From a development perspective, XTL6001 is not designed simply to maximise headline weight loss. By combining the GLP-1R, GCGR and MasR pathways, the programme aims to address weight management, glucose and lipid metabolism, body-composition optimisation and potential renal protection within a single development framework. As the GLP-1 field continues to evolve rapidly, this integrated metabolic–renal approach gives XTL6001 a differentiated profile versus conventional incretin-based therapies and provides a clearer positioning for subsequent global clinical development and potential business development opportunities. From Posters to Oral Presentations: Building International Scientific Visibility EASD and the American Diabetes Association (ADA) Scientific Sessions are among the most prominent international scientific platforms in diabetes and metabolic disease. Research on XTL6001 was first presented in two posters at ADA 2026 in June, followed by two oral presentations at EASD. The progression from posters to oral presentation provided a higher-profile forum for the same development thesis to be presented and discussed with the international scientific community. Conference selection, of course, does not substitute for clinical validation. For an early-stage innovative programme, however, repeated exposure at major international meetings can help increase visibility among clinicians, research institutions and potential industry partners. Notably, XTL6001 presented both weight-management and CKD/DKD research at the same EASD meeting. Obesity care is increasingly moving beyond “weight loss alone” toward broader management of body composition and cardiometabolic, hepatic and renal comorbidities. The ability to deliver benefits beyond weight reduction is therefore becoming an important dimension of next-generation competition. By adding MasR to the GLP-1R/GCGR combination, XTL6001 is designed to incorporate a renal-protection component into its differentiated product profile. Weight Loss, Muscle Preservation and Renal Protection: Differentiation Through a Triple-Target Mechanism According to company disclosures and publicly available scientific data, XTL6001 is a long-acting protein drug candidate and a triple receptor agonist targeting GLP-1R, GCGR and MasR. The programme has completed its Phase I study in China and has received clinical trial authorisation in both China and the United States. In the disclosed Phase I single ascending dose (SAD) study, 25 healthy participants received XTL6001 across a dose range of 37.5–300 mg, with additional participants receiving placebo. The study showed a favourable overall safety and tolerability profile. Dr. Xiangling Wang, Micot Pharma’s Chief Medical Officer (CMO), presented a systematic study comparing XTL6001 The available data also indicate that XTL6001 is designed to deliver benefits beyond the headline weight loss shown on the scale. In preclinical diet-induced obesity (DIO) mouse studies, XTL6001 demonstrated greater weight reduction than semaglutide at equivalent doses and a slower rate of weight regain after treatment discontinuation. At the same dose, and despite overall food intake being comparable to or even higher than that observed with semaglutide, weight reduction was approximately 33% greater, suggesting that the effect may be driven more by increased energy expenditure and fat utilisation than by appetite suppression alone. The studies also showed selective fat loss, restoration of the proportion of muscle mass toward normal levels, a 1.61-fold greater reduction in abdominal fat versus semaglutide, and concurrent improvements in lipid and hepatic parameters, including a reduction in LDL-C of more than 80% (87.2%) and a 90.8% reduction in hepatic triglycerides, with near-complete reversal of hepatic steatosis and normalisation of ALT. These findings point to potential utility in MASH. Importantly, the comparisons with semaglutide were generated primarily in animal studies and should not be interpreted as evidence of superior efficacy in humans. In the renal programme, publicly disclosed studies used multiple animal models of kidney disease. The rationale for the triple-target mechanism can be summarised as follows: GLP-1R primarily supports improvements in metabolism and haemodynamics; GCGR may help protect renal tubules from lipotoxic injury; and MasR is intended to address glomerular structural protection and antifibrotic activity. Together, the three pathways are designed to intervene across metabolic drivers, haemodynamic abnormalities, structural injury and fibrosis in the CKD/DKD disease cascade, rather than acting as a simple combination of independent effects. XTL6001 dose-dependently reduced 24-hour urinary albumin excretion and the urine albumin-to-creatinine ratio (UACR), while improving the glomerular filtration rate (GFR). Across different models, XTL6001 showed dose-dependent reductions in albuminuria: in STZ-induced, uninephrectomised rats, 0.5 mg/kg reduced UACR by 62.9% versus vehicle control and reduced 24-hour urinary albumin by approximately 54.7%; in the alloxan model, the reduction in UACR was approximately three times that seen with finerenone monotherapy; and in a mouse CKD model, 12 mg/kg reduced urinary albumin by 80.2%, with reductions in albuminuria reaching approximately 88% across the three models. The studies also observed reductions in serum creatinine, blood urea nitrogen and serum uric acid. These findings provide further support for the programme’s “weight management–metabolic regulation–albuminuria reduction” rationale. However, the renal benefits remain predominantly preclinical and will need to be validated in randomised controlled studies in patients with CKD/DKD. The Obesity Market Is Moving Into a Multi-Target Era — MasR Gives XTL6001 a Distinct Route The next generation of obesity therapies is already progressing from single-target GLP-1 agents toward GLP-1/GIP dual agonists, GLP-1/GCGR dual agonists and GLP-1/GIP/GCGR triple agonists. Eli Lilly’s retatrutide has advanced into Phase III development, while United Laboratories’ UBT251 is in Phase II, underscoring that “multi-target” activity alone is no longer sufficient to create a durable moat. XTL6001 is differentiated by the fact that its third target is MasR rather than GIPR. According to company disclosures, activation of the MasR pathway is associated with anti-inflammatory and antifibrotic effects, promotion of muscle-protein synthesis, improvement in mitochondrial function and induction of mitochondria-mediated thermogenesis. This gives XTL6001 a development rationale that is more naturally centred on renal protection, proteinuria and broader multi-organ metabolic benefits, rather than on cross-trial comparisons of headline weight-loss efficacy where no head-to-head evidence exists. From a capital-markets and business-development perspective, XTL6001’s successive appearances at ADA and EASD, together with its upcoming presentation of hyperuricaemic nephropathy research at ASN Kidney Week 2026, are helping the programme build continuous visibility across the diabetes, obesity and nephrology communities. Presenting at international scientific meetings is not a transaction in itself, nor can it replace human efficacy data, but it can create additional touchpoints with potential licensing, co-development and regional partners. Ultimately, the asset’s value will depend on whether clinical studies in humans can validate the hypotheses around quality of weight loss, body-composition improvement and renal protection; whether its safety and tolerability profile remains competitive; and whether indications such as CKD/DKD can demonstrate reproducible and clinically translatable benefits. If these elements are progressively validated, XTL6001 could establish a more distinctive global development path in the increasingly crowded GLP-1 landscape through a combined positioning around high-quality weight management, metabolic improvement and potential renal protection.
- Global Molecular Sieves Market Size, Share, and Trends - Forecast 2026-2032 | USD 7.38 Billion by 2032 as Gas Processing and High-Purity Production Drive 5.93% CAGRBoost ROI with AI-enabled monitoring, lifecycle services, efficient regeneration, regional stocking and dual sourcing to reduce downtime, waste and replacement costs
- Graphene Electronics Market - Global Forecast 2026-2032 | 33.76% CAGR Fuels a USD 5.72 Billion Opportunity Across AI, Sensors, Flexible Devices, and Energy StorageMaximize ROI by targeting high-value use cases, validating system gains through pilots, using AI to improve yields, and reducing scale-up risk through partnerships and multi-source supply
- Global Permanent Magnets Market Size, Share, Trends, and Forecast 2026-2032 | Electrification, EVs, and Renewable Energy Drive 5.58% CAGR Toward USD 39.55 Billion"Permanent Magnets Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
- atNorth to develop new data center in Salo, FinlandThe planned site will support critical digital infrastructure while creating opportunities for local collaboration, energy partnerships and heat reuse. — atNorth, the leading Nordic high-density colocation and built-to-suit data center provider, today...
- Savills Hong Kong Celebrates 40th AnniversaryHONG KONG, Oct 5, 2026 - International real estate consultancy Savills Hong Kong is celebrating its 40th anniversary this year. Since establishing its presence in Hong Kong in 1986, the company has grown in tandem with the city, witnessing the evolution of Hong Kong’s property market and the transformation of its urban landscape. To mark this significant milestone and express its gratitude to all employees who have been part of this journey, Savills Hong Kong has launched two special anniversary initiatives: a “Savills Hong Kong 40th” themed tram [branding] campaign and the distribution of limited-edition commemorative Octopus cards to all Hong Kong employees. These initiatives aim to share this proud moment with the team. Double-Sided Themed Tram Travels Across Hong Kong Island, Bringing the Company’s Founding Spirit to the Streets Savills Hong Kong has announced the launch of the 40th anniversary themed tram that travels through the streets and lanes of Hong Kong Island. The tram body features a unique double-sided design with one side features with vibrant bright yellow to reflect the pulse of the city, while the other uses deep navy blue to echo the night view of Victoria Harbour. The tram is printed with Company’s brand philosophy, “Helping People Thrive Through Places and Spaces”, demonstrating the Company’s spirit of providing people-oriented service after four decades of deep-rooted engagement in Hong Kong’s real estate market. Savills Hong Kong 40th Anniversary Themed Tram This initiative is particularly meaningful as it marks the continuation of Hong Kong Tramways’ first tram body painting collaboration with a commercial enterprise. Beyond carrying forward the tram’s longstanding role as a moving part of Hong Kong’s cityscape, the project also creates new possibilities for partnerships between commercial enterprises and local public transport brands. The company would also like to express its sincere gratitude to Hong Kong Tramways for its support, which enabled colleagues to personally participate in and contribute to this unique initiative. Savills Hong Kong colleagues take part in the Employee Painting Day To celebrate this occasion, the company has held its “Employee Painting Day” on 28 September at Shau Kei Wan Tram Depot. Colleagues from the property management and agency teams painted the tram body together. Through their creativity, teamwork and commitment to colour parts of the tram design, integrating Hong Kong’s unique tram culture into the company’s 40th anniversary milestone. Subsequently, on 30 September, the company held a launch ceremony at Whitty Street Tram Depot, hosted by Mr Raymond Lee, Chief Executive Officer, Greater China of Savills and the management team. Mr Lee painted a stroke on the commemorative tram, officially completing this co-created 40th anniversary artwork while ranging the tram bell to symbolise the official launch of the themed tram. The distinctive “ding ding” sound of Hong Kong trams is not merely a sound of the city; it also symbolises moving forward, connection and the beginning of a new journey. The participation of management symbolises management standing together with colleagues and working as one. Savills hopes that through this “mobile celebration stage” travelling across Hong Kong Island could bring the city’s energy and the brand’s colours into the community, and to share the joy of its 40th anniversary with colleagues and the public. Mr. Raymond Lee, Chief Executive Officer, Greater China of Savills, and members of the management team attend the launch ceremony Limited-Edition Commemorative Octopus Cards Presented to All Employees A Keepsake Symbolising Shared Growth In addition to the public-facing tram campaign, the company is also extending its anniversary celebration to every employee with a specially designed “Savills Hong Kong 40th Anniversary Commemorative Octopus Card” created for the team. Featuring Hong Kong’s skyline as its centrepiece, the card uses clean lines to depict landmark buildings on both sides of Victoria Harbour, while a gradient colour palette adds depth to the design. The company’s bespoke 40th anniversary logo and the Savills brand name are incorporated into the upper-right corner. Understated and refined, the overall design makes the card both practical and collectible. As an essential part of daily life in Hong Kong, the Octopus card is more than simply a commuting tool – it is more like a companion in their daily lives. Through this limited-edition commemorative card, the company hopes to honour the contributions and shared journey of every employee over the past 40 years, to express its appreciation for their professionalism, dedication and passionate service in their respective roles, and to celebrate how their collective efforts have carried the company through every market cycle to achieve today’s success. Savills Hong Kong 40th Anniversary Commemorative Octopus Card Harnessing the Power of Teamwork to Shape the Next Chapter Since 1986, Savills Hong Kong and generations of employees have together witnessed the company’s development alongside the city’s transformation. The company’s 40th anniversary is not only an opportunity to look back on its past achievements, but also a new starting point from which to look ahead. Mr Raymond Lee, Chief Executive Officer, Greater China of Savills, said: “This year marks an important milestone as we celebrate 40 years in Hong Kong. The double-sided themed tram travelling across Hong Kong Island and the limited-edition commemorative Octopus card presented to every colleague perfectly embody the two things we have always cherished: progressing alongside the city of Hong Kong and growing together with our people. I would like to express my sincere gratitude to every colleague for their dedication and trust over the years, and to the people of Hong Kong for their continued support. Looking ahead, we will continue to uphold our philosophy of ‘Helping People Thrive Through Places and Spaces’, working hand in hand with our employees, clients and partners to create many more remarkable chapters together.” About Savills For over 170 years, Savills has been helping people thrive through places and spaces. Listed on the London Stock Exchange, we have more than 42,000 professionals collaborating across over 70 countries, delivering unrivalled coverage and expertise to the world of commercial and prime residential real estate. By applying world research data and trends to local and global settings, we’re able to empower our clients with insights from the forefront of the industry – bringing their aspirations to life through innovative, tailor-made solutions. Whether we are working with a global corporate looking to expand, an investor seeking to sustainably optimise their portfolio, or a family trying to find a new home, we help our clients make better property decisions.
- DJS Law Group LLPFluence Energy, Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - FLNCThe DJS Law Group reminds investors of a class action lawsuit against Fluence Energy, Inc. ("Fluence" or "the Company") (NASDAQ: FLNC) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated...